Jefferies Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Jefferies Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,640	Closed	-$55K	–	2142
2019 Q4	$55K	Sell	14,640 -8,540	-37%	-$39.9K	﹤0.01%	2440
2019 Q3	$123K	Buy	23,180 +3,008	+15%	+$16K	﹤0.01%	2466
2019 Q2	$77K	Buy	+20,172	New	+$87.1K	﹤0.01%	2317

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Jefferies Group's CPRX Position: Q1 2020 in Review

Jefferies Group sold out of Catalyst Pharmaceutical (CPRX) in Q1 2020, closing a stake of 14,640 shares — an estimated $55K sold.

Jefferies Group first reported a position in CPRX in Q2 2019 and held it in 3 quarters. The position peaked at $123K in Q3 2019. 131 funds tracked by Wall St. Rank hold CPRX as of Q1 2020.

Jefferies Group reported no remaining Catalyst Pharmaceutical position as of Q1 2020 after selling out during the quarter.
Jefferies Group sold 14,640 Catalyst Pharmaceutical shares in Q1 2020, an estimated $55K.
Jefferies Group first reported a position in Catalyst Pharmaceutical in Q2 2019 and held it in 3 quarters.
Jefferies Group's Catalyst Pharmaceutical position peaked at $123K in Q3 2019.
131 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.